Zeltiq Aesthetics Inc (ZLTQ) : Terra Nova Asset Management added new position in Zeltiq Aesthetics Inc during the most recent quarter end. The investment management firm now holds 20,265 shares of Zeltiq Aesthetics Inc which is valued at $682,323 , the company said in a statement filed on Jul 26, 2016 with the SEC.Zeltiq Aesthetics Inc makes up approximately 1.13% of Terra Nova Asset Management’s portfolio.
Other Hedge Funds, Including , Calamos Wealth Management added ZLTQ to its portfolio by purchasing 7,318 company shares during the most recent quarter which is valued at $246,397. Zeltiq Aesthetics Inc makes up approx 0.05% of Calamos Wealth Management’s portfolio.Simplex Trading reduced its stake in ZLTQ by selling 5,122 shares or 78.06% in the most recent quarter. The Hedge Fund company now holds 1,440 shares of ZLTQ which is valued at $46,627. Zeltiq Aesthetics Inc makes up approx 0.01% of Simplex Trading’s portfolio.Cutler Group Lp reduced its stake in ZLTQ by selling 6,197 shares or 83.8% in the most recent quarter. The Hedge Fund company now holds 1,198 shares of ZLTQ which is valued at $37,689.
Zeltiq Aesthetics Inc opened for trading at $33.65 and hit $34.03 on the upside on Friday, eventually ending the session at $33.95, with a gain of 0.92% or 0.31 points. The heightened volatility saw the trading volume jump to 5,25,202 shares. Company has a market cap of $1,339 M.
On the company’s financial health, Zeltiq Aesthetics Inc reported $-0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.24. The company had revenue of $64.50 million for the quarter, compared to analysts expectations of $61.87 million. The company’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
ZELTIQ Aesthetics Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product the CoolSculpting System is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells which are needed to perform procedures using its CoolSculpting system. As of December 31 2014 it had an installed base of 3176 CoolSculpting systems installed across approximately 2688 practices across the world. As of December 31 2014 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.